Track market-moving stories before they get noisy

PITTSBURGH, May 19, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today announced that it has commenced an underwritten public offering of senior notes (the "Notes Offering"). The exact amount and terms of the Notes Offering will depend upon market conditions and other factors.

Kennametal Inc. Announces Pricing Terms of Cash Tender Offer for Debt Securities PR Newswire PITTSBURGH, May 26,

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Kennametal delivers advanced tooling and materials for demanding industrial sectors, leveraging innovation and a global customer base.

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed patients – – Deep responses with 80% (24/30) MRD negativity among evaluable CRc responders – – Robust transplant rate with 45% (19/42) of patients proceeding to transplant and 63% (12/19) resuming revumenib post-transplant – – Encouraging durability with median overall survival after transplant not reached –  – Combination was generally well-tolerated – NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the Phase 1/2 SAVE trial of an all-oral regimen of Revuforj® (revumenib), decitabine/cedazuridine, and venetoclax in relapsed or refractory (R/R) NPM1 mutated (NPM1m), KMT2A-rearranged (KMT2Ar), or NUP98-rearranged (NUP98r) acute myeloid leukemia (AML) were published in the Journal of Clinical Oncology and simultaneously presented at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden. Revuforj is the first and only menin inhibitor that is FDA approved for patients one year and older with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options or R/R acute leukemia with a KMT2A translocation as determined by an FDA-authorized test.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2026. Financial Results Corcept's first quarter 2026 revenue was $164.9 million, compared to $157.2 million in the first quarter of 2025. F.

Corcept Therapeutics (CORT) came out with a quarterly loss of $0.3 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago.

Corcept Therapeutics Inc. (NASDAQ:CORT) shares are up on Friday as the company reported significant findings from its Phase 2 DAZALS study, demonstrating an 87% reduction in the risk of death for patients with amyotrophic lateral sclerosis (ALS) compared to those receiving a placebo.

Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint.

The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.

Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

[url="]Manhattan Associates Inc.[/url] (Nasdaq: MANH), the global leader in native AI-empowered supply chain commerce solutions, today announced a major additi

LAS VEGAS--(BUSINESS WIRE)--At Momentum 2026, Manhattan unveils Sightline, a new capability within ActivePlanning.

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).

On May 28, 2026, Manhattan Associates Inc (MANH) shares rose 3.3% to a current price of $143.18. The stock has experienced a 52-week range of $119.06 to $247.22

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).

ATLANTA--(BUSINESS WIRE)--Manhattan announces winners of its 2026 Manhattan Value Partner (MVP) Excellence Awards.

Manhattan Associates, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).

MANH's cloud growth and raised outlook are offset by services utilization risks and mix pressures, keeping execution concerns front and center for investors.

MANH leans into cloud growth and AI, but restructuring, macro risks, and rising competition cloud near-term outlook, making it a cautious hold for investors.